Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart

Overview of attention for article published in Basic Research in Cardiology, October 2011

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (76th percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

patent: 15 patents

Citations

dimensions_citation: 89 Dimensions

Readers on

mendeley: 61 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 15 patents that reference this research output.

Methods for treating or mitigating cardiotoxicity characterized by inhibition of…

Grant US-11839614-B2

United States of America

Uses

Grant US-11759465-B2

United States of America

Substituted furanopyrimidine compounds as PDE1 inhibitors

Grant US-11434247-B1

United States of America

Combinations of PDE1 inhibitors and NEP inhibitors

Grant US-11166956-B2

United States of America

Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors

Grant US-10981916-B2

United States of America

Uses

Grant US-10398698-B2

United States of America

Combinations of PDE1 inhibitors and NEP inhibitors and associated methods

Grant US-10285992-B2

United States of America

Organic compounds

Grant US-10238660-B2

United States of America

Organic compounds

Grant US-10131671-B2

United States of America

Organic compounds

Grant US-10010553-B2

United States of America

Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases

Grant US-9801882-B2

United States of America

PDE1 inhibitory compounds and methods

Grant US-9763948-B2

United States of America

Organic compounds

Grant US-9546175-B2

United States of America

NOVEL USES

Application EP-2956141-A4

European Patent Office

NOVEL USES

Application EP-2956141-A1

European Patent Office